RxDoctor Payments Data

Xiang Hon Lin, MD

Internal Medicine · Monterey Park, CANPI 1578520771

Payments from drug & device makers

$3,077in general payments, 2019–2025

Across 130 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$578
  • Lilly USA, LLC$363
  • GSK$360
  • Amarin Pharma, Inc.$307
  • AbbVie$274
  • Gilead$240
  • plus $955 from 15 others

What the payments were for

  • Food & beverage$3,077100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,077 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$45,088
Medicare patients
108
Services billed
423

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol82$69,914
JanuviaSitagliptin Phosphate89$63,322
EliquisApixaban53$54,692
JardianceEmpagliflozin42$45,979
TrulicityDulaglutide31$40,117
VascepaIcosapent Ethyl83$38,665
ProliaDenosumab21$34,770
Icosapent Ethyl87$25,112
OzempicSemaglutide17$23,394
EntrestoSacubitril/Valsartan17$16,042
TradjentaLinagliptin16$13,079
XareltoRivaroxaban19$11,943
DapagliflozinDapagliflozin Propanediol16$8,707
Atorvastatin Calcium612$6,183
Combivent RespimatIpratropium/Albuterol Sulfate12$5,722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$204$69,91482 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$77$64,77970 claims
MerckJanuvia$48$63,32289 claims
PfizerEliquis$168$54,69253 claims
Lilly USA, LLCTrulicity$363$40,11731 claims
AmgenProlia$578$34,77021 claims
Novo NordiskOzempic$67$23,39417 claims
Johnson & JohnsonXarelto$48$11,94319 claims
GSKShingrix$360$2,42511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Monterey Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →